Intellect Neurosciences Inc. (fka ILNS)

[wEaReLeGiOn]

Good heavens. Pfizer spent untold millions of dollars trialing the "drug" for AD. Guess what? It failed. It's hardly a secret, nor is it a secret why ILNS is a PINKSHEET pennystock, trading under a bloody penny. The man behind ILNS is also currently behind bars in a federal pen for stock fraud, specifically but not limited to ILNS. Pfizer has all the research data (which they own) and are free to use the drug (under the licensing agreement with ILNS) for any drug they see fit. The $2MM "payment" that ILNS is claiming Pfizer owes them, was for successful milestone trial data as it pertains to AD. It failed, and the phase III trails were halted.

As I've mentioned before, ILNS doesn't have the high-ground in this dispute over a $2MM milestone payment. The "milestone" turned out to be a road apple, and Pfizer assumed a poorly written licensing agreement when Pfizer bought out Élan and Wyeth, and inherited the trial/development.

http://en.wikipedia.org/wiki/Bapineuzumab

On August 6, 2012, Pfizer Inc. and Johnson & Johnson said they are ending development of an intravenous formulation of bapineuzumab. Testing showed the drug did not work better than placebo in two late-stage trials in patients who had mild to moderate Alzheimer's disease.[10]

Élan announced that Johnson & Johnson, on July 16, 2013, had discontinued Phase 2 testing of the subcutaneous formulation of bapineuzumab.[11] Insider trading

Mathew Martoma, formerly of S.A.C. Capital Advisors, was convicted in February 2014 of insider trading[12] on news passed by neurologist Sid Gilman of the cancellation of bapineuzumab's testing[13]

http://mobile.reuters.com/article/companyNewsAndPR/idUS116143+15-Jul-2010+GNW20100715

"Phase 3 clinical trials, is being co-developed by Pfizer and Johnson & Johnson, and Ponezumab, in Phase 2 trials, is being developed by Pfizer. Both drug candidates are based on the use of antibodies that uniquely bind molecular signatures at the ends of beta amyloid formed when the Aß toxin is generated. This is the fundamental principle of Intellect's ANTISENILIN(R) technology, which is intended to promote the clearance of amyloid protein away from sites of damage in the brain while minimizing the potential for adverse effects that may result from less specific binding" -Dr. Daniel Chain

It doesn't work. Dr.Chain has moved on from "INTELLECT" because he wasn't being paid. "INTELLECT" is a file folder, and they can't afford to protect their IP because a) it doesn't work, and b) attorneys don't work for free on marginal cases over trivial amounts of money ($2MM milestone). Please note there are NO damages being sought by INTELLECT, because THERE ARE NONE. The only "evidence" of damages were brought to bear my part-time employee and sometimes attorney, Elliot Maza. His affidavit was so poorly written and laughable to the court (Pfizer is out to ruin us) that INELLECT's own attorney, didn't even bother to offer anything to the court, other than Maza's paranoid rant.


Pfizer its defense state they stopped using Ponezumab.This ongoing phase II trial is factual proof it did not and they continue to advance Ponezumab draining the lifes blood out of Intellect Neuroscience making it fight this phoney artifical defense causing much damage to the company ILNS and its shareholders which I'm one and I've been devastated.

This link is all thats needed and judge Oing should issue sanctions against the defense attorneys its clients for what is outright open lies to the court.